What Clarithromycin PH Treats: Main Uses and Benefits

Clarithromycin is commonly used to manage a range of infections caused by susceptible bacteria, providing supportive symptom relief in key therapeutic domains. It is relevant for easing symptoms related to physical discomfort in the lungs and airways, such as those associated with pneumonia, acute bronchitis, and sinusitis. It is also applied in addressing localized inflammation from skin and soft tissue infections like cellulitis, as well as common infections of the ear and throat. In a more specialized context, it is a key component in regimes for addressing Helicobacter pylori, and it is considered relevant for managing serious atypical infections like the Mycobacterium avium Complex (MAC). This diverse application means it helps manage symptoms that often interfere with daily functioning.

“Its role is to address the infectious agent, which supports the patient during difficult episodes by easing the overall symptom burden.”

Quick Fact: Relief for Inflammation This medication assists with maintaining functional stability in conditions characterized by periods of heightened symptoms by is used for managing conditions and associated inflammation.

Regulatory References

1. NIH MedlinePlus overview on Clarithromycin

Eligibility and Restrictions for Clarithromycin PH

Absolute Contraindications (Must Not Use): Use of Clarithromycin PH is contraindicated in patients with a known hypersensitivity to macrolide antibiotics or a history of QT prolongation or ventricular arrhythmia. It is also contraindicated in individuals with severe hepatic failure combined with renal impairment, or a history of cholestatic jaundice linked to prior use. Furthermore, it must not be used alongside specific high-risk medications, including cisapride, pimozide, ergot alkaloids, and the statins lovastatin and simvastatin.

Age and Life-Stage Limitations:

• Infants under 6 months: Safety and efficacy have not been established.
• Children under 12 years: The tablet formulation is not recommended.
• Pregnancy and Lactation: Use is not recommended unless no appropriate alternative therapy is available, as the medicine is excreted into human milk.

Conditional Use: Patients with severe renal impairment (creatinine clearance less than 30 mL/min) are eligible for use, but require a regulatory-mandated reduction of the dosage by one-half. Caution is also advised in patients with general hepatic impairment.

Contraindicated Combinations

Clarithromycin PH is strictly contraindicated for co-administration with several medicinal products due to the risk of severe drug interactions, as documented in official prescribing information. These prohibited combinations include Astemizole, Cisapride, Domperidone, Pimozide, and Terfenadine, because co-administration may result in QT prolongation and life-threatening cardiac arrhythmias. Additionally, Lovastatin and Simvastatin are contraindicated because clarithromycin significantly increases their plasma concentration, raising the risk of myopathy including rhabdomyolysis. Co-administration with Ergot Alkaloids (Ergotamine, Dihydroergotamine) is prohibited due to the risk of acute ergot toxicity and vasospasm.

Pharmacokinetic and Timing Restrictions

Clarithromycin is documented as a strong inhibitor of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the transporter P-glycoprotein (P-gp). This mechanism leads to increased systemic exposure and plasma concentrations of numerous co-administered drugs that are substrates for these systems, such as Digoxin, Omeprazole, and Carbamazepine. Exposure of clarithromycin itself may be reduced by strong CYP3A4 inducers like the herbal product St. John’s wort. To manage specific interactions, Zidovudine and Clarithromycin must be administered at least 4 hours apart. Furthermore, the combination with Colchicine is strictly contraindicated for patients with concurrent renal or hepatic impairment due to the heightened risk of toxicity.

How Clarithromycin PH Works

Clarithromycin functions as a bacteriostatic agent by targeting the core molecular machinery required for bacterial replication. The molecule binds specifically and reversibly to the 23S ribosomal RNA (rRNA) component within the bacterial 50S ribosomal subunit. This interaction physically obstructs the peptide exit tunnel, thereby inhibiting protein synthesis by preventing the elongation of the peptide chain (translocation). This key molecular blockade leads to the cessation of bacterial growth and proliferation.

Beyond this primary action, the drug exhibits secondary mechanistic properties, including subtle modulation of host inflammatory pathways by influencing pro-inflammatory mediators. Its chemical structure also enables accumulation within phagocytic immune cells. This characteristic acts as a delivery system, maintaining high concentrations of the active molecule directly at the site of deep-seated tissue biological conflict.

The mechanistic effectiveness is constrained by bacterial defenses: alteration of the 23S rRNA binding site by erm genes or the presence of active efflux pumps prevents the drug from achieving the necessary molecular interaction.

Official Administration Guidelines

Clarithromycin PH is administered primarily via the oral route as immediate-release (IR) tablets, extended-release (ER) tablets, or an oral suspension. In specific circumstances where oral therapy is not feasible, the medicine may be administered via intravenous (IV) infusion.

Administration Schedule and Dosing

The required frequency is dependent on the formulation. Immediate-Release tablets and the oral suspension are typically prescribed for dosing twice daily, maintaining a stable concentration. The Extended-Release tablets are designed to be taken once daily at a 1000 mg dose. The standard adult IR dose range for many approved uses is 250 mg to 500 mg per administration. For H. pylori eradication, the dose is generally 500 mg twice daily as part of a multi-drug regimen.

Procedural Use Constraints

The timing of administration relative to food is critical for the ER form. Extended-Release tablets must be taken with food to ensure their intended drug release over time; however, IR tablets and the oral suspension may be taken with or without food. It is an official requirement that ER tablets be swallowed whole and not crushed, cut, or chewed, as this alters the release mechanism. The standard treatment duration for most infections is a fixed 6 to 14 day course.

Population-Specific Adjustments

Official instructions mandate dose modification for certain populations. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the standard dosage must be reduced by 50% to prevent drug accumulation. Pediatric administration (6 months to 12 years) is determined by an official weight-based formula (7.5 mg/kg twice daily) using the reconstituted oral suspension.

Evidence for Community-Acquired Pneumonia (CAP)

Research has explored clarithromycin in the context of Community-Acquired Pneumonia (CAP), often through Randomized Controlled Trials (RCTs) examining its use as an add-on treatment to standard antibiotics. These studies primarily monitored outcomes related to systemic or functional imbalance, such as how time to clinical stability and changes in inflammatory biomarkers were measured. Findings describe patterns observed in these studies, but long-term outcomes and effects when used alone in severe cases are not fully established.

---

Evidence for Infections of the Skin, Airways, and Sinuses

Clarithromycin was evaluated in research exploring conditions like acute bronchitis, sinusitis, and skin and soft tissue infections (SSTI). The evidence base for these indications is derived from clinical studies reviewed for regulatory filings, typically involving comparative trials. These studies examined outcomes related to physical discomfort over defined, short-term treatment intervals. For many of these long-standing uses, the follow-up durations were limited to the end of the treatment period, and current regulatory data relies mostly on assessments of formulation equivalence.

---

Research on H. pylori Eradication

Research was studied for clarithromycin's role in multi-drug regimens to manage H. pylori. RCTs were used to explore how eradication outcomes and the rates of antimicrobial resistance were measured in adults with confirmed H. pylori infection. Data show patterns related to measurements of eradication success rate that exhibited variability across geographical regions. Research describes that measured outcomes may be lower in settings with resistant strains, and certainty remains low for success in regions where resistance is known to be high (e.g., above 15%).

---

Long-Term Studies and Follow-up

The main research base involves studies with generally short-term (7 to 14 days) or intermediate (4 to 8 weeks) follow-up periods, and the durability of the response over many months or years is not well characterized.

---

Evidence in Special Populations

Research has explored clarithromycin use in specific patient groups, including studies evaluating the oral suspension formulation in pediatric patients (children) for acute changes from infections like otitis media. Studies also examined adults stratified by disease severity and specific comorbid conditions. However, data for other groups, such as pregnant populations, remain insufficient.

Key Studies & References

1. ACCESS Trial: A randomised, double-blind placebo-controlled trial to examine the effect of adding oral clarithromycin to standard-of-care antibiotics in hospitalised patients with CAP
2. The prevalence of clarithromycin-resistant Helicobacter pylori isolates: a systematic review and meta-analysis (used for resistance rates and variability)
3. Public Assessment Report (PAR) for Clarithromycin oral suspension (used for pediatric/suspension formulation and general indications)

Common questions about Clarithromycin PH (FAQ)

---

Q: What types of respiratory infections is Clarithromycin PH typically used for?

Official regulatory documents indicate that Clarithromycin PH is used to address both lower respiratory tract infections, such as pneumonia and bronchitis, and upper respiratory tract infections. This includes common conditions like pharyngitis (sore throat), tonsillitis, and sinusitis.

Q: Can Clarithromycin PH affect liver function test results?

Official product information states that the drug carries a risk of hepatotoxicity, which is damage to the liver. This can involve an increase in liver enzymes, which are detected via lab tests. These enzyme increases may signal hepatocellular or cholestatic hepatitis.

Q: Are there any specific foods or beverages that are described as interacting with Clarithromycin PH?

Regulatory information indicates that grapefruit juice is described as interacting with Clarithromycin. This interaction can affect how the body processes the medicine, potentially delaying the time the drug reaches its highest concentration in the bloodstream.

Q: Can Clarithromycin PH cause increased sensitivity to sunlight or skin reactions?

The official product information documents the possibility of severe adverse skin reactions, such as Stevens-Johnson Syndrome (SJS). Less severe skin symptoms, including general rash or pruritus (itching), are also noted in regulatory reports.

Q: What are the common symptoms of a Clarithromycin PH allergy, according to official patient information?

According to official patient information, a severe allergic reaction (hypersensitivity) may be signaled by symptoms. These can include hives, difficulty breathing, or swelling that affects the face, lips, tongue, or throat.

Q: What is the purpose of the different strengths or dosages of Clarithromycin PH tablets?

Official dosing information explains that different tablet strengths, such as 250 mg or 500 mg, are used to address infections of varying severity or specific types. For example, a 500 mg dose is commonly included in multi-drug regimens used for H. pylori eradication.

Q: Does Clarithromycin PH commonly cause feelings of tiredness or dizziness?

Regulatory reports list dizziness as a less common side effect associated with the use of Clarithromycin PH. Additionally, unusual fatigue or weakness is described as a potential symptom of liver injury, which is a serious adverse reaction.

Q: What information is available regarding Clarithromycin PH and potential changes in hearing?

Official adverse event reporting has documented observations of transient hearing loss (temporary changes in hearing). This effect is mainly noted when the drug is administered at higher dosages.

Q: Does Clarithromycin PH interact with common over-the-counter pain relievers?

Regulatory text notes that Clarithromycin is a strong inhibitor of the CYP3A4 enzyme, a system responsible for metabolizing many drugs. This suggests a theoretical interaction with some common over-the-counter pain relievers, such as acetaminophen.

Q: Does grapefruit juice affect how Clarithromycin PH is processed by the body?

Yes, studies have examined the effect of grapefruit juice on the body's processing of Clarithromycin. Evidence indicates that consuming grapefruit juice may delay the time it takes for the drug and its active form to reach their highest concentration in the blood.

Q: How does Clarithromycin PH interact with warfarin or other blood-thinning medicines?

Regulatory warnings state that Clarithromycin can interact with blood-thinning medicines like warfarin, potentially leading to increased exposure of warfarin in the body. This interaction carries a risk of increased bleeding, and the need for close monitoring is noted in official warnings.

Q: How soon after stopping Clarithromycin PH does the drug completely leave the body?

Pharmacokinetic data, documented in official sources, can provide insight into how the medicine is eliminated. These studies indicate that the half-life of the active substance and its primary metabolite is approximately 5 to 7 hours.

Q: What is the general information available on the risk of developing antibiotic resistance with Clarithromycin PH?

Official regulatory labels contain information regarding the potential for antibiotic resistance. They note that resistance to macrolides is possible in certain bacteria, and official information refers to the potential need for susceptibility testing when clinically relevant to help ensure the drug remains effective.

Q: Has any official body provided guidance on specific considerations for use in patients with compromised immune systems?

Official regulatory documents specify the drug's use in certain infections common among patients with compromised immune systems. Specifically, Clarithromycin PH is indicated for the treatment and prevention of Mycobacterium avium complex (MAC) infection.

Q: Are there specific warnings about Clarithromycin PH use in patients with a history of myasthenia gravis?

Official product warnings explicitly state that the use of Clarithromycin PH may worsen the symptoms of a pre-existing condition known as myasthenia gravis. This is included as a serious precaution in the regulatory labeling.

Q: Can Clarithromycin PH cause changes to blood sugar levels in people with diabetes?

Official labeling includes warnings regarding potential interactions with certain diabetes medications. Due to this potential for interaction, the need for close monitoring of blood sugar levels is referenced in the regulatory labeling.

Q: What is the general information about Clarithromycin PH's use in dental procedures?

The drug is referenced in guidelines as an option for the prevention of bacterial endocarditis in patients who have a penicillin allergy before specific dental procedures.

Q: Are there any specific warnings for patients with known porphyria using Clarithromycin PH?

Regulatory safety constraints indicate that the combination of Clarithromycin with ranitidine bismuth citrate is strictly contraindicated (must not be used) in patients with a known history of porphyria.

Storage Requirements

Clarithromycin tablets must be stored at Controlled Room Temperature (20 C to 25 C), protected from light and excess moisture, and kept in the tightly closed container it was dispensed in. For the oral suspension, the dry granules must be stored below 25 C. Once mixed (reconstituted), the liquid suspension must not be refrigerated or frozen and is only stable for 14 days. Any unused reconstituted product must be discarded after this time limit.

Disposal Instructions

All forms of this medicine must be kept out of the reach and sight of children. To dispose of expired or unused Clarithromycin, the FDA recommends using a drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (like coffee grounds or dirt), sealed in a bag, and thrown into the household trash. This medicine is not on the list of drugs recommended for flushing.